Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EMA advises on how to prevent medication errors with new forms and indications

This article was originally published in SRA

Executive Summary

In yet another move prompted by the new EU pharmacovigilance legislation, companies proposing to market products similar to ones already on the market are being asked to take extra steps to prevent potential medication errors, particularly involving substances that have a narrow therapeutic index1.

You may also be interested in...



Coronavirus Notebook: COVAX Wellcomes Latecomers, Sanofi/GSK Sign Canadian Supply Deal

The Australian government is investing in two candidate vaccines being developed in Melbourne, French firm Avaxia is looking at the virucidal potential of an antibacterial compound, and Canada has ordered millions of specialist vials and syringes from an advanced materials science firm based in Alabama.

UK/EU Industry ‘Still Working In The Dark’ On Post-Brexit Regulation

As the final scheduled round of post-Brexit trade talks begins amid growing concern over the prospect of a deal and the pervasive threat of COVID-19, the pharmaceutical industry in the UK and the EU have issued an urgent call for an MRA on medicines GMP. They also want to see a one-year phase-in of medicines-related aspects of the Northern Ireland Protocol.

EU Politicians Squeeze Pharma Execs On Coronavirus Vaccine Contracts

With coronavirus cases again on the rise in many European countries, members of two EU parliamentary committees asked industry representatives to explain why details of COVID-19 vaccine supply agreements are being kept under wraps.

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel